HIGHLIGHTS
- who: Oliver Schnell from the National Institute for Health and Care Excellence NYHA have published the research: CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes, in the Journal: (JOURNAL)
- what: The aim of this research work is to collect evidence-based support for updating the recommendations in the guideline regarding the role of different medications in clinical practice including newer medications like a nonsteroidal MRA.
- how: The same observation was made regarding death from any cause (4.5% in the empagliflozin group vs. 5.1% in the placebo group HR 0 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.